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A B S T R A C T
Sox proteins are a family of lineage-associated transcription factors. They regulate expression of genes involved
in control of self-renewal and multipotency in both developmental and adult stem cells. Overexpression of Sox
proteins is frequently observed in many different human cancers. Despite their importance as therapeutic tar-
gets, Sox proteins are difficult to ‘drug’ using structure-based design. However, Sox protein localisation, activity
and interaction partners are regulated by a plethora of post-translational modifications (PTMs), such as: phos-
phorylation, acetylation, sumoylation, methylation, and ubiquitylation. Here we review the various reported
post-translational modifications of Sox proteins and their potential functional importance in guiding cell fate
processes. The enzymes that regulate these PTMs could be useful targets for anti-cancer drug discovery.
1. Introduction
Within many tissues, undifferentiated multipotent stem and pro-
genitor cells sustain the turnover of new cells during tissue homeostasis
and repair. Developmental transcription factors (TFs) and their asso-
ciated core transcriptional apparatus are key determinants of cell type
identity. These orchestrate the balance between self-renewal and dif-
ferentiation. In many types of cancer, these developmental TFs (e.g.
HOX, FOX, SOX and bHLH proteins) become deregulated and drive
“stemness”, enforcing an immature cellular phenotype and limiting
possibilities for terminal cell differentiation [1]. Excellent reviews have
discussed the diverse SOX protein functions across stem cells, devel-
opment and cancer [2,3]. Here we focus our discussions on the function
of SOX post-translational modifications (PTMs) and whether these
could be critical targets for new anti-cancer drug discovery.
Developmental TFs often operate in a combinatorial manner, as ‘co-
operatives’ and are often termed master regulatory transcription factors
[4]. In many cancers changes in gene expression which underpin tu-
mour growth, are driven by key oncogenic signalling TFs, such as:
STAT, SMAD, TCF, ETS [5,6]; these are the transcriptional effectors of
LIF, TGFbeta, Wnt and ERK pathways, respectively. Convergence of
these oncogenic, or signalling TFs, with master developmental TFs
likely occurs by their shared binding/co-localisation at key enhancers
or superenhancers, which drives robust expression of cell type specific
target genes [5]. This is why high-grade cancers typically have histo-
logical resemblance to the corresponding foetal tissue or regenerating
tissue from the cell of origin. They exploit the molecular apparatus used
by stem cells. Targeting cancer stem-cell-like identity could therefore be
achieved by targeting the activity of these core TFs.
2. ‘Drugging’ transcription factors
There are∼1600 TFs encoding genes in the human genome [7]. TFs
form protein complexes that activate or repress transcription at specific
target genes, by binding to regulatory sites in the genome. TFs typically
have a modular design, with core DNA binding domains separate from
effector domains (e.g. activation, repression or chromatin-interacting).
Many also harbour non-structured domains, such as stretches of ala-
nine, proline or glycine residues, and these confer an important func-
tional role in supporting the formation of biophysically separated sub-
nuclear domains, termed transcriptional condensates.
Disrupting these TFs, or their complexes, using small molecules has
proven difficult due them targeting protein-protein interactions, with
large, flat surface areas which do not offer druggable binding pockets.
They have therefore been viewed as difficult to targets to ‘drug’ using
classic structure-based design methods that have been so successful for
targets with catalytic sites. Alternative strategies are therefore needed.
PTM is a dynamic, reversible process adapted to rapidly transmit
signalling information. PTM dynamics are frequently centred on en-
zymes that catalyse the addition, removal and “reading” of these sites.
In the last 10–20 years there has been great interest in targeting cancer
signalling pathways, which often involve complex networks and
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cascades of post-translation modifications (PTMs) [8]. Genetic disrup-
tion to these core cancer pathways (e.g. receptor tyrosine kinase sig-
nalling) is frequently observed across many human cancers. Therefore,
the tools for studying and identifying new small molecule inhibitors are
well established. Perhaps the most widely explored PTM is phosphor-
ylation, which is catalysed by kinases and reversed by phosphatases [9].
PTMs can be broadly separated into 2 categories: chemical mod-
ifications (e.g. phosphorylation/methylation/acetylation) and small
protein modifications (e.g. ubiquitylation/SUMOylation). Searching for
post-translational modifications (PTMs) which might be critical for TF
activity, might offer a wealth of new targets, as the associated enzymes
could be amenable to inhibition. However, there remain extensive gaps
in our knowledge. Below, we will focus discussion on how these mod-
ifications and associated interactions provide a novel target for cancer
therapies. How do these PTMs arise? What is their key function? Can
they be modulated using small molecules? SOX proteins are attracting
particular attention, as their overexpression is a recurrent feature of the
majority of human cancers (Fig. 1).
Fig. 1. Sox proteins are highly expressed in different cancers. Heatmap showing the median fkpm value of Sox family expression from RNA-seq of The Cancer
Genome Atlas [10].
Fig. 2. A schematic of the domain structure of
SOX family transcription factors. Sox groups A-
H are grouped based on their DNA-binding
high mobility group (HMG) domain. The do-
main architecture of SOX proteins varies be-
tween each group and harbour additional mo-
tifs, such as Transcriptional Activation/
Repressor domains (SOX domains reviewed in:
Ref. [3]). SOX30 is uniquely expressed in hu-
mans and is related to SOXD family proteins
through the remanence of a coiled-coiled do-
main. Proteins are drawn to scale.
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3. SOX proteins
The male sex determination gene SRY was the founding member of
the SOX family (from which the family takes its name: Sex determining
region Y (SRY)-related high-mobility group HMG-box) [11,12]. SOX
proteins bind to the DNA sequence motif ATTGTT (or related se-
quences) through the three alpha helices within the HMG domains that
form a L-shaped domain that interacts with the DNA minor groove
[13,14]. This interaction is thought to trigger a conformational change,
bending the DNA, and this may contribute to Sox function [15].
However, it is also the case that Sox factors have affinity to ‘pre-bent’
DNA that is present within nucleosomes – wrapped around the histone
octamer – explaining their activity as pioneer factors (see pioneer factor
discussion below).
The SOX transcription factor family comprises of over 20 members
of which there are 11 subgroups categorised on the basis of their HMG
box and associated domains (Fig. 2). These are classified into groups
termed A-H, depending on the similarity of the HMG domains [3,16].
Sry, is the only member of the SoxA group [17]. The SoxB family is
subdivided into two subgroups with similar HMG domains: SoxB1 and
B2. SoxB1 members (Sox1, Sox2 and Sox3) have a transcriptional ac-
tivation domain in their C-terminus whereas SoxB2 (Sox14, Sox21)
have transcriptional repression domain in the C-terminus [18,19]. The
SoxG protein, Sox15, is related to SoxB; however its molecular func-
tions remain unclear [20]. SoxC/E/F are analogous to SoxB1 with N-
terminal HMG domains and transcriptional activation domains; how-
ever, there are significant differences in protein sequences beyond these
domains.
Notably, SoxE family (Sox8, Sox9 and Sox10) contain a N-terminal
dimerisation domain which plays a role in remodelling chromatin
[21–23]. SoxD have C-terminal HMG domains and N-terminal coiled-
coil domains which mediate SoxD family dimerization and thereby
preferential binding to pairs of DNA recognition sites [24]. These fac-
tors are also less stringent in DNA binding motifs resulting in putative
SoxD binding sites at most promoters/regulatory regions [25]. Loosely
related to SoxD is the SoxG protein, Sox30, which is the most divergent
member, these Sox proteins contain the remnants of a coiled coil do-
main and a C-terminal HMG domain [26]. PTMs may therefore have
specific effects on each SOX member based on their distinct protein
domain architectures. For this review modified residues will be stated
in the species variant (mm: mus musculus; hs: homo sapien) in which
the study was conducted.
4. Consequences of SOX post-translation modifications
Sox protein PTMs have been reported across the spectrum of
common modifications, including: phosphorylation, acetylation, me-
thylation, SUMOylation, and ubiquitylation (Fig. 3). These modifica-
tions represent druggable targets through targeting the enzymes that
catalyse either their addition or removal. Many known PTMs have an
annotated function; however, numerous proteomic mass spectrometry
screens have revealed novel and functionally uncharacterised PTMs on
Sox factors [27–34]. An increasingly long list of new PTMs has
therefore emerged, and we do not know the identity or role of the as-
sociated enzyme. These provide many new avenues to investigate and
will likely be corrupted in cancer. There are several strategies that have
been uncovered in which SOX activity can be modulated (Fig. 4), and
these are discussed below.
5. PTMS that modulate DNA binding properties
Critical to Sox protein function is its ability to bind sequence-spe-
cific sites in the genome. Either disrupting or promoting DNA interac-
tions may therefore influence Sox activity and shift key targets, either
oncogene or tumour suppressor. All 20 Sox factors interact with DNA
through a highly positive binding surface in the HMG box, which ex-
hibits strong evolutionary conservation, and has been studied through
numerous NMR and X-ray crystallography studies [35–38]. Sox protein
modifications that modulate DNA binding therefore represent a tract-
able target to disrupt/promote DNA interactions. However, it is notable
those reported PTMs of Sox proteins which influence DNA binding lie
outside of the HMG box, which suggests that it may not be directly
accessible to modification (Fig. 3; Table 1) [39].
Protein phosphorylation adds a phosphate group to either a tyr-
osine, threonine or serine. The addition of negative charge to a protein
can result in a distinct change in its biophysical properties. In Sertoli
cells SRY is phosphorylated by PKA, at the N-terminal of its HMG box
which positively regulates DNA-binding and results in inhibition of
basal promotor activity located downstream of an SRY DNA-binding
site concatemer [35]. This could be due to phosphorylation altering
protein conformation of SRY which promotes binding to DNA. In lung
squamous cell carcinoma, Sox2 is phosphorylated by PKCι at Thr116
(hs; mm Thr118) and this is necessary for occupancy at the HHAT
promoter leading to promotion of the stem cell-like phenotype [40].
Sox2 Thr116 (hs; mm Thr118) resides between the HMG domain and a
consensus nuclear localisation sequence in Sox2 indicating that phos-
phorylation may modulate HMG-DNA interaction or nuclear localisa-
tion [40]. As there were no apparent localisation defects, these data
suggest that modulating DNA interactions around the HMG box in-
crease the ability of Sox proteins to bind to DNA, which could possibly
be due to the introduction of a conformational change which increases
affinity to DNA and/or chromatin.
SUMOylation (small ubiquitin-like modifier) is an important PTM
that often alters the activity of many different transcription factors
when it is covalently attached to a lysine residue. This is analogous to
ubiquitination, with a series of enzymatic reactions leading to attach-
ment of these proteins to a target protein. SUMOylation is most com-
monly reported to play a role in repressing transcriptional activity.
Sox2 is SUMOylated, and this can influence its transcriptional activity.
An example is Lys247 of Sox2 (mm; hs Lys245) which under normal
conditions binds to the Fgf4 enhancer but following conjugation of
SUMO1 at Lys247 (mm; hs Lys245) there is reduced binding [41]. Sox2
SUMOylation therefore can negatively regulate transcription at key
target genes through impairing of DNA binding (Fig. 4).
Fig. 3. Posttranslational modifications of SOX2
and SOX9. PTMs of SOX2 and SOX9 are well-
explored and highlight clusters of methylation,
phosphorylation, acetylation, sumolyation and
ubiquitination. Post-Translational modifica-
tions identified through low throughput ap-
proaches are annotated. Proteins are drawn to
scale.
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6. Perturbing SOX family transcriptional activity
A related mode of action for PTMs is to influence SOX protein-
protein interactions. Protein partner changes can dramatically switch
activation, repression or transcriptional specificity of targets (e.g. motif
binding). Phosphorylation often acts as an anchor for protein-protein
interactions (e.g. dimerisation) and therefore can stimulate recruitment
of transcriptional coactivators/repressors (Fig. 4). Sox2 is phosphory-
lated at Thr118 (mm; hs Thr116) by Akt and this has been reported to
enhance the transcriptional activation of Sox2 in mouse embryonic
stem cells (ESCs) and also enhancing the activity of Sox2 in repro-
gramming of mouse embryonic fibroblasts to induced pluripotent stem
cells [42]. Sox2 is also phosphorylated by Cyclin-dependent kinase
(CDK) at Ser37 (hs; mm Ser39) and Ser251 (hs; mm Ser253) with
proposed functional roles in reprogramming to pluripotency [43].
Ser37 (hs; mm Ser39) and Thr118 (mm; hs Thr116) are flanking the
HMG box which could confer conformational changes and/or promote
interaction with transcriptional co-regulators.
Another example of phosphorylation modulating transcriptional
activity is the phosphorylation of Sox9 at Ser64 (hs/mm) and Ser181
(hs/mm) by PKA in response to BMP/TGF signalling, which results in its
transcriptional activation, in turn driving Sox9 dependent changes like
delamination and osteochondrogenic differentiation [44–47]. These
amino acids lie near its dimerisation domain (Ser64) and HMG box
(Ser181) which indicates that phosphorylation may modulate dimer-
isation of Sox9 and/or its interaction with DNA. Phosphorylation may
therefore either alter the different dimers that Sox9 can make by re-
cruiting different SoxE members (heterodimers vs. homodimers), pre-
venting dimerisation, or modulating DNA interactions. In melanoma,
Sox10 which is phosphorylated at Ser24 (hs/mm) and Thr240 (hs/mm)
at sites which are predicted to be controlled by MAPK/CDK phos-
phorylation [48]. These sites are also highly conserved amongst SoxE
family members suggesting a broad method of targeting these proteins
in various different cancers [48]. Loss of these sites triggers an small
increase in Sox10 transcriptional activity [48]. In all, SoxE family
members have a wide range of phosphorylation sites that regulate their
transcriptional activity by either increasing activity or changing ac-
tivity. SoxE family members have been shown to be important in both
maintenance of neural crest progenitors and ensuring their proper dif-
ferentiation [49]. It could therefore be speculated that phosphorylation
at the residues identified above could act as a TF switch that influences
cell differentiation state. This could be exploited in a cancer therapeutic
approach to influence the fate of cancer stem cells, such as driving
terminal differentiation. Alterations to phosphatases might also influ-
ence SOX activity. Okadaic acid can broadly inhibiting serine/threonine
phosphatases and results in an increase in Sox18 transcriptional ac-
tivity. Sox18 transcriptional activity is reduced when prospective sites
are mutated [50]. These sites are suggested to be downstream of either
PKA or CK2 [50].
Methylation and acetylation result in the addition of a hydrophobic
moiety to a protein, in the form of either a methyl group or acetyl group
[51,52]. These PTMs have been extensively studied in the context of
histone tail modifications. However, many proteins can be modified in
this way [53]. Methylation has indeed been reported for Sox2 in ESCs,
and is regulated by the coactivator-associated arginine methyl-
transferase 1 (CARM1). CARM1 mediates Sox2 transactivation by me-
thylating Sox2 at Arg113 (hs; mm Arg115) resulting in enhanced oli-
gomerization – possibly through the formation of dimers or larger
protein complexes [54]. Interestingly, the chromatin-bound pool of
Sox2 has a reduced methylation compared to unbound, suggesting that
methylation may be important in loading and retaining Sox2 to tran-
scriptional sites. Arg113 (hs; mm Arg115) flanks the HMG-domain of
SOX2 which suggests that methylation may perturb DNA binding or
that a region near the HMG is important in oligomerisation. CARM1 has
also been shown to methylate Sox9 at multiple arginine residues near/
on its HMG box domain in chondrocytes. This modification disrupts
Sox9 interaction with beta-catenin which increases Cyclin D1 expres-
sion and therefore drives cell cycle progression [55]. It is unclear if this
is due to Sox9 repressing beta-catenin transcriptional activity through
its interaction, or if the methylation drives Sox9 transcriptional activity.
In ESCs, SOX2 is SUMOylated by the SUMO-E3 ligase, Pias3, which
results in the impairment of the interaction with Oct4 and downstream
Fig. 4. Schematic diagram illustrating how various post translational modifications of Sox factors modulate their function such as transcriptional actitivity, DNA
binding, protein stability, pioneer activity and nuclear localisation.
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disruption of key transcriptional targets, such as Nanog [56]. Further-
more, Sox6 sumoylation of either Lys404 (hs/mm) and Lys417 (hs/mm)
perturbs its transcriptional activity [57]. Disruption of the SUMO
modification site or its conjugating enzyme, Ubc9, result in an increase
in transcriptional activity in both Sox2 and Sox6 [56,57]. Ubc9 has also
been found to interact with Sox10 to drive its sumoylation at Lys55/357
(hs/mm) which leads to repression of its transcriptional activity at 2 of
its target genes, GJB1 and MITF (by altering how it interacts with its
cofactors EGR2 and PAX3) [58]. Furthermore, SUMOylation of SOX10
is antagonised by predicted MAPK sites at Thr240 and/or Thr244 (hs/
mm) however Lys55 (hs/mm) SUMOlyation is required for SOX10
transcriptional activity [59]. Sox9 is SUMOylated at Lys61 (hs/mm),
Lys253 (hs/mm), Lys398 (hs; mm Lys396) during chick development,
within the neural crest progenitors during delamination. These Sox9
sites are required for its interaction with the zinc-finger-type tran-
scription factor, Snail2, suggesting that SUMOylation is driving tran-
scriptional activity of this complex [46]. This SUMOylation of Sox9 is
mediated by Sox9 phosphorylation (Ser181/Ser211 (hs/mm)
[44–47,60–64]. Thus, while modification with SUMO most commonly
results in a suppression of transcriptional activity of Sox factors, it can
also act to activate transcription as seen from the above papers (Fig. 4).
With regard to acetylation, Sox9 interacts with and is acetylated by
KAT5 (Tip60) at Lys61 (hs/mm), Lys253 (hs/mm), Lys398 (hs; mm
Lys396). These are also SUMOylation sites, indicating that there is a
Table 1
Table of Sox protein post translational modifications.
SOX Protein Modification Species identified
in
Human
Residue
Catalytic enzyme PTM Effect Citation
SOX2 Acetylation Mouse K35 Unknown Unknown [91]
SOX2 Phosphorylation Mouse/Human S37 CDK Enhances transcriptional activity [43,98]
SOX2 Acetylation Mouse K58 Unknown Unknown [91]
SOX2 Acetylation Mouse K65 Unknown Unknown [91]
SOX2 Acetylation Mouse/Human K73 p300/CBP Promotes nuclear export [91]
SOX2 Acetylation Mouse K87 Unknown Unknown [91]
SOX2 Acetylation Mouse K95 Unknown Unknown [91]
SOX2 Acetylation Mouse K103 Unknown Unknown [91]
SOX2 Acetylation Mouse K109 Unknown Unknown [91]
SOX2 Methylation Mouse R111 CARM1 Enhances transcriptional activity [30]
SOX2 Acetylation Mouse K115 Unknown Unknown [91]
SOX2 Methylation Mouse R117 SETD7 Promotes degradation [75]
SOX2 Phosphorylation Human T116 PKCι Required for promotor occupancy/Enhances
transcriptional activity/Promotes stablisation
[40,42]
SOX2 Acetylation Mouse K121 Unknown Unknown [91]
SOX2 Ubiquitination Mouse K121 Unknown Promotes Degradation [86]
SOX2 SUMOlylation Mouse K245 PIAS, UBC9 Impairs DNA binding/Impairs Protein interactions/
Reduces transcriptional activity
[41,56]
SOX2 Phosphorylation Mouse/Human S251 CDK1, MAPK1/3, Aurora
Kinase A
Promotes SOX2 associated transcriptional programs [43,79,98]
SOX4 Acetylation Human K95 KAT5 Chromatin Remodelling [73]
SOX6 Phosphorylation Mouse/Human T119 CDK5 Promotes degradation [87]
SOX6 SUMOylation Human K404 UBC9 Represses SOX6 transcriptional activity [57]
SOX6 SUMOylation Human K417 UBC9 [57]
SOX9 Acetylation Human K61 KAT5 Enhances transcriptional activity [65]
SOX9 SUMOylation Chicken K61 Unknown [46]
SOX9 Phosphorylation Mouse/Human/
Chicken
S64 Upstream: BMP, TGF Kinase:
PKA,
Enhances transcriptional activation [44–47,63,64]
SOX9 Methylation Mouse R74 CARM1/PRMT4 Possibly enhances transcriptional activity [55]
SOX9 Methylation Mouse R152 CARM1/PRMT4 [55]
SOX9 Methylation Mouse R177 CARM1/PRMT4 [55]
SOX9 Methylation Mouse R178 CARM1/PRMT4 [55]
SOX9 Methylation Mouse R179 CARM1/PRMT4 [55]
SOX9 Phosphorylation Mouse/Human/
Chicken
S181 Upstream: BMP, TGF, Rho
kinase Kinase: PKA,
Enhances transcriptional activity [44–47,60–63]
SOX9 Phosphorylation Mouse/Human S211 PKA, p38, SMAD [45,64]
SOX9 Phosphorylation Human T236 Upstream: PI3K/AKT/mTOR
Kinase: GSK3
Promotes degradation [88]
SOX9 Acetylation Human K253 KAT5 Enhances transcriptional activity [65]
SOX9 SUMOylation Chicken K253 Unknown [46]
SOX9 SUMOylation Chicken K398 Unknown [46]
SOX9 Acetylation Human K398 KAT5 [65]
SOX10 Phosphorylation Mouse/Human S24 Predicted: CDK, MAPK Represses transcriptional activity/Promotes
degradation
[48]
SOX10 Phosphorylation Mouse/Human S45 Predicted: CDK, MAPK Slight increase in activity [48]
SOX10 SUMOylation Human K55 Ubc9 Represses transcriptional activity [58]
SOX10 Phosphorylation Human S224 Unknown Unknown [48]
SOX10 Phosphorylation Human S232 Unknown Unknown [48]
SOX10 Phosphorylation Human T240 Predicted: CDK, MAPK Represses transcriptional activity [48]
SOX10 Phosphorylation Human T244 [48]
SOX10 SUMOylation Human K246 Unknown Unknown [58]
SOX10 SUMOylation Human K357 Ubc9 Represses transcriptional activity [58]
SOX11 Phosphorylation Mouse S30 Unknown Promotes nuclear localisation [92]
SOX11 Phosphorylation Mouse S133 PKA Fine-tunes transcriptional activity [99]
SOX18 Phosphorylation Mouse S278/S281 Predicted: PKA, CK2 Enhances transcriptional activity [50]
SRY Phosphorylation Human S31-33 PKA Promotes DNA binding [90]
SRY Acetylation Human K136 p300 Promotes nuclear import [90]
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potential switch between acetylation and SUMOylation [65]. This
modification increases Sox9 transcriptional activity. It would therefore
be interesting to examine how these two modifications interact and
how acetylation affects Snail2 interaction and how SUMOylation effects
KAT5 interaction.
Altogether the above studies indicate that targeting the upstream
enzymes that modulate (add/remove) PTMs on specific Sox protein
transcriptional activity would have dramatic effects on Sox protein
activity and function – although in complex and difficult to predict
ways.
7. Disrupting pioneer activity
Eukaryotic genomes are organised into distinct chromatin territories
– either compacted or more open and accessible – that stabilise the
existing patterns of gene expression, helping to preserve cell type
identity and limit inappropriate cell fate conversions. It is therefore
critical to understand how transcription factors such as SOX members
interact with distinct forms of chromatin. It has generally been viewed
that transcription factors would bind most strongly to naked DNA, and
become more restricted in their binding once the DNA becomes
wrapped around histones, forming the nucleosome. However, it is be-
come increasingly clear that certain transcription factors can strongly
interact with nucleosome bound DNA. For example, SOX2 binds nu-
cleosomes more strongly than naked DNA [66]. Transcription factors
with these properties can therefore access closed chromatin and target
silent genes for subsequent reactivation; they have been termed ‘pio-
neer’ factors [67]. This might be a key biochemical feature under-
pinning their importance as master regulators of cell type and as re-
programming factors [16,68]. Related to this, recent studies have
suggested that binding to nucleosomes may impart the ability of pio-
neer factors to bind mitotic chromatin, acting as ‘book-marking’ pro-
teins [69]. This mitotic bookmarking ability has been found to be more
prevalent than previously thought and has been reported for Sox2 in ES
cells [70]. The mitotic bookmarking function play a crucial role for
maintaining cell identity through the cell cycle stages (reviewed in: Ref.
[71]), which has direct implications on cycling and quiescent cancer
cells. The role of PTM of Sox factors in regulating their pioneer activ-
ities is currently unknown yet could provide a key regulatory step.
Although not a Sox factor, HMG-14, which shares features with Sox
proteins, is acetylated by p300 which weakens its interaction with
nucleosomes [72]. We would speculate that large modifications like
SUMOylation/ubiquitylation would disrupt the intricate chromatin-
transcription factor interactions; however, phosphorylation, methyla-
tion, and acetylation would be harder to predict. Mechanistic insights
have been made by studies of how Sox4 orchestrates chromatin re-
modelling during myoblast differentiation. Sox4, a SoxC member, in-
teracts with and is acetylated by the acetyltransferase, KAT5, at Lys95
(hs/mm). This facilitates SOX4 recruitment to DNA and through the
KAT5 chromodomain aids with chromatin remodelling [73]. This
highlights that even small PTMs can modulate Sox family pioneer ac-
tivity (Fig. 4).
8. Degrading SOX family members
Sox protein levels are tightly controlled to maintain cellular
homeostasis. Sox levels are modulated throughout the cell cycle, and
transcriptional regulation is in part achieved by varying steady-state
protein levels. Proteins can be downregulated through extinguishing
transcription, but also by post-translational control via protein de-
gradation pathways. The most studied protein degradation is the ubi-
quitination system, although other PTMs can modulate this, such as
phosphorylation [74]. Regulation of protein degradation pathways is
therefore a clear route to perturbing the promiscuous activity of Sox
factors in cancer (Fig. 4).
PTMs are not mutually exclusive, and an example of how they
cooperate or antagonise one another, is the interplay between methy-
lation, ubiquitination and phosphorylation on Sox2. In mouse ESCs,
Sox2 protein expression is regulated by a novel methylation/phos-
phorylation switch. Setd7 efficiently monomethylates Sox2 at Lys119
(ms; hs Lys117). This methylation controls Sox2 protein stability by
recruiting the ubiquitin ligase WWP2, whose catalytic HECT domain
binds to the methylated lysine which in turn ubiquitylates Sox2 which
results in its degradation [75]. In contrast, Akt1 phosphorylates SOX2
at Thr118 (mm; hs Thr116) which antagonises Lys119 (mm; hs Thr117)
methylation and prevents subsequent degradation [75]. Additionally,
SOX2 phosphorylation at Thr116 (hs; ms Thr118) by AKT antagonises
degradation by the ubiquitin ligase UBR5 by preventing ubiquitination
at Lys115 (hs; mm Lys117) [76]. It has been suggested that SOX
phosphor-Thr118 (mm; hs Thr116) lies downstream of IGF-1 in a novel
RIT/AKT/SOX2 axis [77]. Phosphorylation of SOX2 Ser251 (hs; mm
Ser253) by ERK1/2 is also reported to promote autophagic degradation
in nasopharyngeal carcinoma stem cells [78]. Mitotic SOX2 Ser251 (hs;
mm Ser253) phosphorylation is also reported to be catalysed by Aurora
A which maintains that a stem cell-like state [79]. These data demon-
strate the importance of Sox factor protein stability in regulating cell
fate.
The role of protein ubiquitination in regulating Sox factor stability is
also exemplified in the stability of SOX2 during neural stem cell dif-
ferentiation. During neural differentiation, the decrease in SOX2 pro-
tein expression is directly correlated to the expression of the deubiqu-
tinating enzyme, OTUD7B and inversely to the reciprocal ubiquitin
ligase complex, CUL4ADET1-COP1 [80]. Sox2 directly interacts with the
substrate adaptor, COP1 which results in its polyubiquitination on
multiple Lysine residues on Sox2, whereas OTUD7B deubiquinates Sox2
[80]. This modification is distinct from the WWP2 turnover of Sox2
which indicates that there may be differential regulation of Sox proteins
between cell types. The CUL4A complexes are critical in regulating cell
cycle machinery and indicates that Sox2 may have a novel role in the
cell cycle [81]. Ubiquitin can form a polymer chain at any of its seven
lysine residues which regulate, K11 linkages only accounts for a small
percentage the total ubiquitination events in normal mammalian cells
[82]. K11 is associated with proteasomal degradation of cell cycle
components through the anaphase-promoting complex (APC) [83,84].
In addition, APC has been found to regulate neuronal morphogenesis
and differentiation [85]. The generation of K11 linked chains are al-
most specifically driven by the priming E2, Ube2s, which has been
identified as critical for maintaining pluripotency [86]. Interestingly,
Sox2 is K11 ubiquitinated at Lys123 (mm; hs Lys121), thus marking it
for degradation and contributes to Sox2-controlled differentiation to
neuroectoderm [86]. This suggests that Sox2 is degraded at specific cell
cycle stages to allow differentiation and could be manipulated in order
to enforce differentiation of cancer stem cells.
Phosphorylation of proteins at specific residues can alter interac-
tions with the degradation machinery: a phospho-degron. Sox6 is ex-
pressed in differentiating neurons with its expression gradually de-
creases through development. Sox6 is phosphorylated a phospho-
degron at Thr119 (hs/mm) by Cdk5 which regulates Sox6 steady state
protein levels in order to coordinate the proper differentiation into a
post-mitotic state neuron [87]. Another example of a phospho-degron is
on Sox9. Sox9 is phosphorylated by GSK3 kinase at Thr236 (hs/mm),
FBW7 recognises a conserved degron surrounding this site which is
degraded by the SCFFBW7α complex [88]. This was shown to be nega-
tively regulated by a PI3K/AKT/mTOR signalling axis. As shown in
Fig. 1, Sox9 is highly expressed in medulloblastoma; in cases where
FBW7 is dysregulated, Sox9 protein is elevated [88]. Inhibition of PI3K/
AKT/mTOR signalling destabilises Sox9 which renders medullo-
blastoma cells sensitive to cytostatic treatment [88]. Interestingly, this
residue and motif is conserved amongst all SoxE family members which
suggest that there may be a unifying approach to targeting cancers
where SoxE family members are overexpressed (Fig. 1). SOX10, which
is highly expressed in melanoma tumours, was identified to be
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phosphorylated at Ser24 (hs/mm). This site is predicted to be a MAPK/
CDK substrate motif and mutation of this resulted in an increase in
stability of SOX10 suggesting the presence of a phosphodegron [48].
These findings further the understanding of Sox10 protein levels
and provides possibly novel targets for more effective combinatorial
therapeutics. Modulation of the stability of Sox proteins may provide a
way to compensate against the effects of oncogenic or SOX2 genomic
amplifications observed in cancers. Therefore, targeting the pathways
upstream with activators or agonists may provide a unique way to
decrease Sox expression.
9. Mediating SOX nuclear localisation
Within the Sox HMG domain there is a conserved region which is a
predicted to be a nuclear localisation signal (Reviewed in: Ref. [89]).
Disruption of Sox factor localisation (less nuclear) has been shown upon
perturbation of the acetylation of SRY by p300 at Lys136 (hs; ms not
conserved) where this residue increases its interaction with importin-
beta [90]. This is reversed by HDAC3. These data suggest that SRY
acetylation may play an important regulatory role. Acetylation by p300
can also promote the export of other Sox factors. SOX2 is acetylated at
Lys75 (mm. hs Lys73), within its HMG box, which disrupts it nuclear
localisation and promotes nuclear export [91]. Disruption of this acet-
ylation promotes SOX2 nuclear localisation and maintains its target
gene expression. Therefore, p300 represents an interesting target for
regulating the localisation of Sox proteins that are overexpressed in
cancer (Fig. 4).
Sox11 is transiently active during neurogenesis which ensures pre-
cise execution of the neurogenic program. Sox11 phosphorylation at
Ser30 (hs/mm), a residue N-terminal of the HMG box, promotes nuclear
localisation [92]. The upstream kinases for this PTM remain unclear
and could represent an interesting and druggable target to regulate
Sox11 localisation.
10. Future perspectives
This review has summarised the numerous roles of PTMs that in-
fluence Sox proteins. There is a wealth of possibilities to influence SOX
activity via modulation of PTMs. SOX PTMs that are at the core of
controlling “stemness” can act as molecular switches for various cancer
types. It is therefore important to understand how to target these using
either small molecules, gene therapies or immunotherapies. The ther-
apeutic exploitation of PTMs other than phosphorylation is still in its
infancy. Phosphorylation, which is the most well studied PTM, led to 38
small molecules approved for clinical applications [93]. The targeting
of other PTMs remains more elusive, with acetylation being of the next
most frequently targeted (e.g. HDAC inhibitors).
In addition to finding novel sites on Sox factors for the pre-existing
array of PTMs, there is the possibility that unknown PTMs may be
having a novel function in regulating Sox activity. There is much to
explore. For example, the recent discovery of non-canonical phos-
phorylation events which are highly liable or the recently identified
PTMs like CoAlation [94,95]. However, a challenge will be to identify
PTMs and associated enzymatic activities that are cell type/lineage
specific to prevent off target tissue toxicities. Furthermore, it remains
unclear how PTMs will effect changes to the biophysical properties of
Sox factors which are required to initiative transcription. A biophysical
mechanism may explain the robust and high levels of expression of
many developmental master regulatory TFs: namely, the aggregation of
these high valency proteins into complexes and formation of phase-
separated nuclear microcompartments, or condensates, that provide
robust and high levels of expression [96]. Indeed, it has been identified
that phosphorylation can prevent phase-separated protein condensation
of core transcriptional machinery [97].
11. Concluding remarks
Although many genetic or RNAi loss of function studies have
identified critical roles for Sox proteins in cancer, unfortunately less is
known about the biochemistry of Sox proteins and how they could be
modulated using small molecules. PTMs have been identified which
regulate almost every aspect of Sox function, but the functional roles,
cross-talk between these modifications needs further investigation and
is not easily dissected. With improved understanding of the mechanisms
by which PTMs are added/removed opportunities will open up for new
strategies to tackle many human cancers. Such targeted can potentially
disrupt tumour growth without the significant tissue toxicities that are a
feature of current cytotoxic or anti-mitotic treatments.
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